ImmunityBio Reports Record Q1 Revenue and Strong Cash Position, Driven by ANKTIVA Growth

summarizeSummary

ImmunityBio announced strong preliminary Q1 2026 financial results, including record net product revenue of $44.2 million and a healthy cash balance of $380.9 million, driven by ANKTIVA's continued commercial success.

check_boxKey Events

• Record Q1 2026 Net Product Revenue

  Reported preliminary net product revenue of $44.2 million for Q1 2026, representing a 168% increase year-over-year compared to Q1 2025 and a 15% sequential increase from Q4 2025.

• Strong Cash Position

  Ended Q1 2026 with an estimated $380.9 million in cash, cash equivalents, and marketable securities.

• ANKTIVA Commercial Momentum

  ANKTIVA unit sales volume increased by 168% year-over-year in Q1 2026, with the product now approved or authorized in 5 regulatory jurisdictions, encompassing approximately 34 countries.

• Positive Clinical & Regulatory Updates

  NCCN Clinical Practice Guidelines were updated in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease. Additionally, the pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled, with a supplemental BLA submission on track for 2026.

auto_awesomeAnalysis

ImmunityBio's preliminary Q1 2026 results demonstrate robust commercial execution for ANKTIVA, with significant year-over-year and sequential revenue growth. The substantial cash balance provides financial flexibility, while positive clinical and regulatory updates further strengthen the company's long-term outlook. This official filing confirms the strong preliminary results previously reported by news outlets today. Investors should monitor the final Q1 2026 10-Q for confirmation of these preliminary figures and continued ANKTIVA adoption.